Clinical Study

Regeneron R2810-Onc-1788- A Randomized, Placebo-Controlled, Double-Blind Study Of Adjuvant Cemiplimab Versus Placebo After Surgery And Radiation Therapy In Patients With High Risk Cutaneous Squamous Cell Carcinoma

Posted Date: Jul 8, 2020

  • Investigator: Rekha Chaudhary
  • Specialties: Cancer, Oncology, Skin Cancer
  • Type of Study: Drug

The primary goal is to compare disease-free survival (DFS) of patients with high-risk cutaneous squamous cell carcinoma (CSCC) treated with adjuvant cemiplimab, versus those treated with placebo, after surgery and radiation therapy (RT).


To Be Eligible: Must Have Diagnosis Of High Risk Cscc, Ecog =1, Post-Operative Rt Complete Within 2 To 6 Weeks, No Sccs Arising In Non-Cutaneous Sites, No Other Concurrent Malignancy Within 3 Years, No Prior Systemic Immunotherapy For Cscc, No Allogeneic Stem Cell Transplantation, No Current Or Recent Infection Or Comorbidity That Could Impact Study Treatment


Cscc, Skin Cancer, Cutaneous Squamous Cell Carcinoma

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.